Novo Nordisk A/S: all 1,444 studies

Page 12 of 15. Open to participants first (108), then studies with results posted, then the rest; newest registration first within each.

• Frequency of Episodes of Hypoglycaemia During Treatment With Biphasic Insulin Aspart 30 in Type 2 DiabetesCompletedNCT01487798Phase 4
• An Observational Study of Insulin Aspart and, if Necessary, Insulin Levemir (FlexPen®) in the Evening or at BedtimeCompletedNCT01487421
• Special Survey for Type 1 or Type 2 Diabetic PatientsCompletedNCT01487408
• Special Survey for Paediatric SubjectsCompletedNCT01487382
• Special Survey of Production of Insulin Aspart Specific AntibodyCompletedNCT01487369
• Impact of Professional Societies' Recommendations on Practical Use of Hormone Replacement TherapyCompletedNCT01487304
• Pharmacokinetic Assessment of the Absorption of Estradiol in Postmenopausal Women With Atrophic VaginitisCompletedNCT01486979Phase 1
• Comparison of Insulin Detemir Plus Insulin Aspart With Insulin NPH Plus Human Soluble Insulin in Subjects With Type 1 DiabetesCompletedNCT01486940Phase 3
• Comparison of Insulin Aspart Produced by Current Process and the NN2000 ProcessCompletedNCT01486914Phase 1
• Bioequivalence of Two Insulatard® Formulations in Healthy SubjectsCompletedNCT01486901Phase 1
• Bioequivalence of Two Mixtard® 30 Formulations in Healthy SubjectsCompletedNCT01486888Phase 1
• Observational Study of Safety of NovoMix® 30 Treatment for Type 2 DiabetesCompletedNCT01486875
• Efficacy of Biphasic Insulin Aspart 30 in Subjects With Type 2 Diabetes Failing on OADsCompletedNCT01486862Phase 4
• Long Term Safety of Biphasic Insulin Aspart 30 in Juveniles With Type 1 DiabetesCompletedNCT01486381Phase 3
• Liraglutide or Insulin in Real Life Usage in Patients With Diabetes Mellitus Type 2CompletedNCT01484262
• Bioavailability of Three Oral Formulations for Hormone Replacement Therapy in Postmenopausal WomenCompletedNCT01477632Phase 1
• Observational Registry of the Treatment of Glanzmann's ThrombastheniaCompletedNCT01476423
• A Trial Investigating the Pharmacokinetic Properties of Formulations of NN1218 in Subjects With Type 1 DiabetesCompletedNCT01469143Phase 1
• A Trial Investigating the Effect of NN1250 in Japanese Subjects With Type 2 DiabetesTerminatedNCT01467414Phase 1
• Efficacy and Safety of NovoMix® 30 in Subjects With Type 2 DiabetesCompletedNCT01467401Phase 4
• Long Term Safety and Efficacy of Biphasic Insulin Aspart 30 in Type 2 DiabetesCompletedNCT01467375Phase 3
• Efficacy and Safety of Biphasic Insulin Aspart 30 in Type 1 or Type 2 DiabetesCompletedNCT01467323Phase 3
• Safety and Efficacy of Insulin Aspart in Children With Type 1 DiabetesCompletedNCT01467141Phase 4
• Comparison of Metformin, Repaglinide or the Combination of Both in Subjects With Type 2 DiabetesCompletedNCT01465152Phase 4
• Bioequivalence of Two NovoLog® Formulations in Subjects With Type 1 DiabetesCompletedNCT01464099Phase 1
• A Trial to Test for Bioequivalence Between NN1045 and NN5401 in Subjects With Type 1 DiabetesCompletedNCT01455142Phase 1
• Evaluating Safety of NovoPen® 3 and/or FlexPen® Devices in Routine Clinical PracticeCompletedNCT01454024
• Comparison of Human Insulin Produced by the Current Process and the NN729 Process in Healthy VolunteersCompletedNCT01448070Phase 1
• Investigating the Pharmacokinetic Properties of NN1250 in Healthy Chinese SubjectsCompletedNCT01437592Phase 1
• Changing Diabetes® World TourCompletedNCT01437072
• A Survey to Evaluate Diabetes Management, Control, Chronic Complications, Psychosocial Aspects of Children With Type 1 DiabetesCompletedNCT01435642
• A Survey Collecting Data on Adult Height in Patients With Achondroplasia Treated With SomatropinCompletedNCT01435629
• Trial Investigating the Safety of NNC 0113-0987 in Healthy Male SubjectsCompletedNCT01405261Phase 1
• Evaluating the Safety and Effectiveness of Liraglutide in Subjects With Type 2 DiabetesCompletedNCT01403025
• Bioequivalence of Two Somatropin Products (Norditropin® Versus Genotropin®) in Healthy Adult VolunteersCompletedNCT01401244Phase 1
• A Single Dose Trial of NNC 0155-0000-0004 in Patients With Haemophilia ACompletedNCT01365520Phase 1
• Observational, Safety Study of NovoNorm® (Repaglinide) and Insulin Analogue Combination Therapy in Type 2 Diabetes in KoreaCompletedNCT01355718
• A Survey to Evaluate Diabetes Management, Control, Chronic Complications, Psychosocial Aspects of Diabetic Subjects in IndiaCompletedNCT01351922
• Non-Interventional Study on Safety of Liraglutide in Subjects With Type 2 DiabetesCompletedNCT01345734
• Safety of NNC 0123-0000-0338 in Healthy SubjectsCompletedNCT01334034Phase 1
• Usability and Tolerability of the Norditropin NordiFlex® Injection Device in Children Never Previously Treated With Growth HormoneCompletedNCT01327924
• Effect of Oral Contraceptives After Administration of Semaglutide in Subjects With Type 2 DiabetesCompletedNCT01324505Phase 1
• Survey Evaluating the Psychosocial Effects of Living With HaemophiliaCompletedNCT01322620
• Safety and Tolerability of Insulin Degludec/Liraglutide (A3) in Healthy SubjectsCompletedNCT01319240Phase 1
• Efficacy and Safety Study of Oral Eligen® B12 in Subjects With Low Serum CobalaminCompletedNCT01312831Not applicable
• Observational Study on Safety and Efficacy of NovoSeven® in Subjects With Congenital FVII DeficiencyCompletedNCT01312636
• Oral Cyanocobalamin (Eligen B12) Bioavailability StudyCompletedNCT01311739Not applicable
• A Trial Investigating the Pharmacokinetic Properties of NN1218 in Subjects With Diabetes Mellitus, Type 1CompletedNCT01296438Phase 1
• Investigating Safety and Pharmacokinetics of 2 Different Single Doses of NNC128-0000-2011 in Haemophilia A or B PatientsCompletedNCT01288391Phase 1
• Observational Study on Effectiveness and Safety of Liraglutide in Subjects With Type 2 DiabetesCompletedNCT01288326
• Observational Study on the Use of NovoSeven® for Haemostatic Treatment of Bleeding Episodes in Patients With Acquired HaemophiliaCompletedNCT01285089
• Efficacy of NNC109-0012 in Subjects With Active Rheumatoid ArthritisCompletedNCT01282255Phase 2
• Investigation on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NN9924 in Healthy Male SubjectsCompletedNCT01272973Phase 1
• Investigating Safety and Pharmacokinetics of NNC 0128-0000-2011 Compared to NNC 0128-0000-2021 in Healthy Male SubjectsCompletedNCT01272206Phase 1
• Comparing Insulin Aspart With Fast-acting Insulin Human in Subjects With Type 1 DiabetesCompletedNCT01269606Phase 1
• First Human Dose Study of Anti-IL-20 in Psoriasis: A Study of Safety, Tolerability and Early Signals of Biologic and Clinical EffectsTerminatedNCT01261767Phase 1
• Investigation of the Pharmacokinetic Properties of Biphasic Insulin Aspart 50 in Healthy Chinese SubjectsCompletedNCT01242826Phase 1
• A Single Dose Trial of Recombinant Factor VIII (N8) in Japanese Subjects With Haemophilia A: An Extension to Trial NN7008-3543CompletedNCT01238367Phase 1
• Observational Study Describing the Usual Clinical Practice Use of NovoSeven® in the Home Treatment of Joint Bleeds in Patients With Haemophilia A or B and InhibitorsCompletedNCT01234545
• Safety of NNC 0172-0000-2021 in Healthy Male Subjects and Subjects With Haemophilia A or BCompletedNCT01228669Phase 1
• Observational Study on Efficacy and Safety of Liraglutide in Subjects With Type 2 DiabetesCompletedNCT01226966
• A Multiple Dose Trial of NNC 0151-0000-0000 in Subjects With Rheumatoid ArthritisCompletedNCT01223911Phase 2
• Observational Study on Safety of Room Temperature Stable NovoSeven® in Patients With Haemophilia A or BCompletedNCT01220141
• A Post Marketing Surveillance (PMS) Study of Liraglutide in Subjects With Type 2 Diabetes Mellitus in IndiaCompletedNCT01212133
• First-in-Man Trial of NNC114-0005 in Healthy Subjects and Subjects With Rheumatoid ArthritisCompletedNCT01208506Phase 1
• Safety and Pharmacokinetics of NNC 0129-0000-1003 in Subjects With Haemophilia ACompletedNCT01205724Phase 1
• Comparison of Two Identical NN1250 Formulations in Healthy VolunteersCompletedNCT01193387Phase 1
• Observational Study of NovoPen Echo® on Safety and Treatment Satisfaction in Children and Adolescents With Type 1 DiabetesCompletedNCT01180530
• A Trial Investigating the Exposure of NN5401 in Young Adults and Elderly Subjects With Type 1 DiabetesCompletedNCT01174303Phase 1
• Comparison of the Effect of NN5401 With the Effect of NN1250 and Insulin Aspart in Subjects With Type 1 DiabetesCompletedNCT01173926Phase 1
• A Trial Evaluating the Blood Glucose-lowering Effect of NN1250 in Subjects With Type 2 DiabetesCompletedNCT01154881Phase 1
• Safety of Recombinant Factor XIII (rFXIII) in Healthy Japanese VolunteersCompletedNCT01153997Phase 1
• A Trial Comparing the Effect of NN1250 After Different Routes of Injection in Healthy SubjectsCompletedNCT01151072Phase 1
• A Trial Investigating the Total Exposure of NN5401 (Insulin Degludec/Insulin Aspart) in Children, Adolescents and Adult Subjects With Type 1 DiabetesCompletedNCT01138488Phase 1
• A Trial Investigating the Effect of NN1250 in Japanese Subjects With Type 1 DiabetesCompletedNCT01135927Phase 1
• A Trial Investigating the Effect of NN5401 in Subjects With Type 2 DiabetesCompletedNCT01134224Phase 1
• A Comparison Between Two Formulations of NN5401 in Healthy SubjectsCompletedNCT01125553Phase 1
• A Trial Investigating NN1218 in Subjects With Type 1 DiabetesCompletedNCT01121289Phase 1
• A Trial Investigating NN1218 in Subjects With Type 1 and Type 2 DiabetesCompletedNCT01121276Phase 1
• A Trial Evaluating the Effect of NN1250 at Steady State Conditions in Subjects With Type 1 DiabetesCompletedNCT01114542Phase 1
• Observational Study of the Safety and Efficacy of Norditropin® in Patients With SGA (Small for Gestational Age) Short Stature That Are Still GrowingCompletedNCT01110928
• Observational Study of the Safety and Efficacy of Norditropin® in Adult Patients With Growth Hormone DeficiencyCompletedNCT01109017
• A Two Part Trial Investigating the Safety of NN9925 in Healthy Male SubjectsCompletedNCT01087645Phase 1
• Comparison of Two Vaginal Tablets, Produced at Different Sites, in Postmenopausal Women With Atrophic VaginitisCompletedNCT01085877Phase 1
• Comparison of a Blood Clotting Drug (Recombinant Factor XIII) Produced by Two Different Manufacturers in Healthy Male SubjectsCompletedNCT01082406Phase 1
• An Observational Study Investigating the Safety and Effectiveness of Repaglinide in Chinese PatientsCompletedNCT01077570
• Efficacy Evaluation of Different Medication Combination in Type 2 Diabetes TreatmentCompletedNCT01076842Phase 4
• Comparison of Two NN1250 Formulations in Subjects With Type 1 DiabetesCompletedNCT01076634Phase 1
• Observational Study to Investigate the Occurrence of Bleeding in Postmenopausal Women Treated With Estradiol/NETA for 12 MonthsCompletedNCT01076621
• An Observational Study on Treatment Compliance by Children Treated With Growth HormoneWithdrawnNCT01068639
• Effect of NN5401 in Japanese Subjects With Type 1 DiabetesCompletedNCT01051102Phase 1
• A Two Part Trial Investigating an Anti-obesity Drug in Overweight/Obese Male and Female Healthy VolunteersTerminatedNCT01044108Phase 1
• The Effect of NN1250 in Subjects With Type 2 Diabetes of Different Race and/or Ethnic OriginCompletedNCT01043510Phase 1
• Safety and Tolerability of Anti-IL-20 in Subjects With Rheumatoid ArthritisCompletedNCT01038674Phase 1
• A Two Part Trial Investigating the Safety of NN9924 in Healthy Male SubjectsCompletedNCT01037582Phase 1
• Dose Study in Healthy Males Investigating Safety, Pharmacokinetics and Pharmacodynamics of NNC126-0083 Compared to Norditropin® SimpleXx®CompletedNCT01034202Phase 1
• A Trial Investigating the Concentration in the Blood of NN1250 in Children, Adolescents and Adults With Type 1 DiabetesCompletedNCT01030926Phase 1
• A Two Part Trial Investigating NN1952 in Healthy Subjects and Subjects With Type 1 and Type 2 DiabetesCompletedNCT01028404Phase 1
• Preference Study Between NovoFine® Autocover™ and a NovoFine® 8 mm NeedleCompletedNCT01024218Phase 4
• An Investigation of NNC 0151-0000-0000 in Subjects With Systemic Lupus Erythematosus (SLE)WithdrawnNCT01018238Phase 1

← Novo Nordisk A/S overview and focus areas